CA
NZ
UK
AU
IND
US
Adaptive Biotechnologies (NASDAQ:ADPT) runs clonoSEQ, a test that detects tiny amounts of residual cancer in blood cancers, a diagnostic capability known as minimal or measurable residual disease testing. Fast-growing test volumes lifted revenue and profitability again this quarter, and the company plans to separate …
Adagio Medical (NASDAQ:ADGM) is developing catheters that destroy the faulty heart tissue behind dangerous rhythm disorders, and its clinical results in a hard-to-treat condition are genuinely encouraging. But strong trial data alone doesn't pay the bills, and the company's own accounts point to a …
Adial Pharmaceuticals (NASDAQ:ADIL) is developing AD04, a pill intended to help genetically defined heavy drinkers cut down on alcohol consumption, and the company has recently pointed to a potentially shorter path to FDA approval as encouraging news. That regulatory possibility is real. But a …
Alaunos Therapeutics (NASDAQ: TCRT) shares closed down 25% at $1.20 after the company announced a $1.12 million registered direct offering priced at $1.46 per share, utilizing common equity alongside pre-funded warrants to raiseCapitalintended for operational needs and general corporate uses.
Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares closed down 8% at $0.17 despite the company collaborating with QIMA Life Sciences to assess tapinarof combination therapies for autoimmune skin conditions.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares closed down 31% at $39.75 after the company submitted a New Drug Application for azetukalner targeting focal onset seizures, backed by successful Phase 2b and Phase 3 trial results, while concurrently instituting a temporary enrollment pause across its …
Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares closed up 13% at $2.77 after the company entered into an all-stock acquisition agreement with Santersus AG, resulting in existing XBIO shareholders retaining roughly 15% ownership while Santersus investors secure the remaining 85% of the entity.
Cybin Inc. (NASDAQ: CYBN) shares closed down 12% at $12.37, even as the company was initiated with an Overweight rating by a Barclays analyst, who set a $35 price target on the equity.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) shares closed up 10% at $1.23 after the company published peer-reviewed preclinical data evaluating Telomir-Zn in age-related macular degeneration, demonstrating regulated iron and copper levels, preserved retinal structure, improved visual metrics, and decreased mitochondrial oxidative stress in models.
OS Therapies Incorporated (NYSE: OSTX) reached regulatory consensus alongside European agencies regarding its adaptive Phase 3 framework evaluating OST-HER2 for resected pulmonary metastatic osteosarcoma.
Please wait processing your request...